of eculizumab, our patient was vaccinated against meningococcal infection before the initiation of eculizumab treatment. 5 Unabated complement activation due to the production of mutant factor H may explain the high rate of recurrence of atypical hemolyticuremic syndrome, and overall lack of success of renal transplantation, in patients with factor H mutation. Recent reports have shown that treatment with eculizumab during recurrence can improve renal function. 5, 6 However, we began prophylactic treatment before there was any evidence of recurrence, to maintain chronic suppression of complement activity in an attempt to reduce the risk of progression to graft failure in our high-risk patient with factor H mutation. To date, the patient shows no signs of graft rejection or recurrence of atypical hemolytic-uremic Ten days after renal transplantation, the patient received the first dose of eculizumab. No plasma exchange was performed thereafter. Within 24 to 48 hours after the first dose, platelet counts increased (Panel A). The patient's platelet counts, complement component 3 (C3) values (Panel B), and haptoglobin levels (Panel C) all stabilized in the middle of the normal range during the year since transplantation. Serum creatinine levels have been maintained within the normal range. The gray horizontal lines in Panels A through D represent the lower limit of the normal ranges for platelets (155,000 to 425,000 cells per cubic millimeter), complement C3 (90 mg per deciliter), and haptoglobin (14 mg per deciliter) and the upper limit of the normal range for serum creatinine (0.64 mg per deciliter [57 μmol per liter]), respectively. After the commencement of eculizumab treatment, activation of serum terminal complement complex (TCC) 4 was blocked within 1 day, and the blocking was maintained with the regimen of a dose given every 14 days. An attempt to increase the interval between doses to 21 days (arrows) resulted in an increase in the activated TCC level, indicating that the eculizumab level under this regimen was insufficient to maintain blocking. Dosing every 14 days was resumed. The normal range (5th to 95th percentile) for serum TCC is 3.0 to 22.9 μl per milliliter. To convert values for creatinine to micromoles per liter, multiply by 88.4. 
Days since Transplantation
Eculizumab (started at day 10)
Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following:
• Letters in reference to a Journal article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article. • Include your full mailing address, telephone number, fax number, and e-mail address with your letter. • All letters must be submitted at authors.NEJM.org.
• Letters not related to a
We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the Journal's various print and electronic publications and in collections, revisions, and any other form or medium.
corrections
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events (10.1056/NEJMoa1001122; published on March 14, 2010, at NEJM.org). In Table 1 (page 7) , all values in the Baseline and Last study visit rows under Angiotensin-receptor blocker were incorrect. The article has been corrected at NEJM.org.
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events (10.1056/NEJMoa1001121; published on March 14, 2010, at NEJM.org). In Table 1 (page 7) , all values given for Lipids and for Ratio of urinary albumin to creatinine were incorrect in the Valsartan and Placebo columns, and all values given for Angiotensin-receptor blocker, including the P values, were incorrect. In the Statistical Analysis subsection of Methods (page 3), the first sentence should have begun, "On the assumption that the study would continue until the extended cardiovascular outcome occurred in 1374 patients in the two study groups combined" rather than "... in 1774 patients in the placebo group." The article has been corrected at NEJM.org. 
Effects of Combination Lipid Therapy in
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